a public good project by the
Synthesis
Company
of California

© 2026

Kathryn A. Krueger | doi.page

0 works0 citations0 h-index

Kathryn A. Krueger

Universität Hamburg(DE)Eli Lilly (United States)(US)Mount Sinai Hospital(US)University Medical Center Hamburg-Eppendorf(DE)

Publications by Year

Research Areas

Lipoproteins and Cardiovascular Health, Estrogen and related hormone effects, Inflammatory Bowel Disease, Microscopic Colitis, Celiac Disease Research and Management

Most-Cited Works

→ Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol(2011)412 cited
→ Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis(2023)292 cited
→ The Metabolic Syndrome and Development of Cognitive Impairment Among Older Women(2009)222 cited
→ Effect of Raloxifene on Prevention of Dementia and Cognitive Impairment in Older Women: The Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial(2005)216 cited
→ Cognitive Function in Postmenopausal Women Treated With Raloxifene(2001)197 cited
→ Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial(2000)168 cited

→ Indicators of Lifetime Estrogen Exposure: Effect on Breast Cancer Incidence and Interaction With Raloxifene Therapy in the Multiple Outcomes of Raloxifene Evaluation Study Participants(2001)131 cited

→ Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib(2015)114 cited

→ The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial(2000)92 cited

→ Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study(2016)76 cited